Y-Shaped Ligand-Driven Gold Nanoparticles for Highly Efficient Tumoral Uptake and Photothermal Ablation
Source abstract
Abstract
We report functional gold nanoparticles (AuNP) with antibody-like ligands. These particles consist of Y-shaped ligands and AuNP. Transferrin (Tf) and Tat peptide were linked to each head of a Y-shaped poly(ethylene glycol) (PEG)-containing dopamine at one tail site. Also, Y-shaped ligands (with Tf and Tat peptide) were anchored to the surface of the AuNP as the result of noncovalent conjugation of dopamine and the AuNP. Interestingly, the partial shielding of Tat peptides by large Tf molecules rather improved Tf-mediated endocytosis of the AuNP, while minimizing the natural nonspecific cell interaction of Tat peptides. This system resulted in highly improved in vitro/in vivo tumor-selective uptake over AuNP bearing a single ligand (Tf or Tat peptides). Furthermore, this system resulted in significant enhancement of in vivo photothermal tumor cell ablation under light-irradiation conditions for AuNP. We believe that this design is a promising method to easily modify conventional antibodies or ligands to improve their disease-recognition ability.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biotechnology, The Catholic University of Korea, 43-1 Yeokgok 2-dong, Wonmi-gu, Bucheon, Gyeonggi-do 420-743, Republic of Korea
College of Pharmacy, SungKyunKwan University, 300 Chonchon-dong, Jangan-ku, Suwon, Gyeonggi-do 440-746, Republic of Korea
Research Center for Industrial Chemical Biotechnology, Ulsan Division of Chemical R&BD, Korea Research Institute of Chemical Technology (KRICT), Ulsan 681-802, Republic of Korea
Funding
National Research Foundation of Korea
References (22)
Show source-provided references
1. Schrama D. · Nat. Rev. Drug Discovery · 2006 · 5 · 14710.1038/nrd1957 ↗
2. Wang X. · J. Controlled Release · 2014 · 193 · 13910.1016/j.jconrel.2014.05.028 ↗
3. Young J. S. · Expert Opin. Drug Delivery · 2014 · 11 · 173310.1517/17425247.2014.937420 ↗
4. Lee E. S. · Nano Lett. · 2005 · 5 · 32510.1021/nl0479987 ↗
5. Lee E. S. · J. Controlled Release · 2008 · 132 · 16410.1016/j.jconrel.2008.05.003 ↗
6. Lee E. S. · Angew. Chem., Int. Ed. · 2008 · 47 · 241810.1002/anie.200704121 ↗
7. Jang B. · ACS Nano · 2011 · 5 · 108610.1021/nn102722z ↗
8. Qiu X. · Nat. Biotechnol. · 2007 · 25 · 92110.1038/nbt1320 ↗
9. Derda R. · Molecules · 2011 · 16 · 177610.3390/molecules16021776 ↗
10. Firer M. A. · OA Cancer · 2013 · 1 · 810.13172/2053-3918-1-1-753 ↗
11. Jian J. · J. Biol. Chem. · 2011 · 286 · 3570810.1074/jbc.M111.271585 ↗
12. Wadia J. S. · Nat. Med. · 2004 · 10 · 31010.1038/nm996 ↗
13. Fabregat G. · J. Phys. Chem. B · 2014 · 118 · 470210.1021/jp500959j ↗
14. Barbe K. · Beilstein J. Nanotechnol. · 2014 · 5 · 125410.3762/bjnano.5.139 ↗
15. Kakimoto S. · J. Controlled Release · 2007 · 120 · 24210.1016/j.jconrel.2007.05.001 ↗
16. Park S. Y. · Angew. Chem., Int. Ed. · 2011 · 50 · 164410.1002/anie.201006038 ↗
17. Lee U. Y. · Int. J. Pharm. · 2014 · 471 · 16610.1016/j.ijpharm.2014.05.028 ↗
18. Cho E. C. · Angew. Chem., Int. Ed. · 2010 · 49 · 197610.1002/anie.200906584 ↗
19. Kwag D. S. · J. Controlled Release · 2014 · 187 · 8310.1016/j.jconrel.2014.05.032 ↗
20. Lee J. O. · J. Mater. Chem. B · 2014 · 2 · 636310.1039/C4TB00779D ↗
21. Cheng L. · Chem. Rev. · 2014 · 114 · 1086910.1021/cr400532z ↗
22. Kwag D. S. · Chem. Commun. · 2013 · 49 · 28210.1039/C2CC36596K ↗